A recent study reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds far faster than those who stop traditional diet and exercise regimens.
Published data in a prominent medical journal demonstrates that while overweight people often shed a large proportion of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users buying such medications must be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about a year and a half.
Analyzing Therapies
The analysis, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
The team emphasize that people who shed pounds through diet and exercise typically have a slower weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists believe the mode of action of the jabs is key to understanding the heightened weight return.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations far above than normal may cause the system to produce less of its own natural hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Disease?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the significant potential of weight regain, the therapy should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the jabs describe a sudden resurgence of hunger.
"I experienced something that goes on and I was suddenly extremely hungry," described one woman.
The struggle is compounded if individuals have not developed lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Figures show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are potent agents for weight loss, they are not a magic cure and maintained weight loss relies on integrated behavioural management.
